Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timo Vesikari

Showing results (61-70 of 211) with videos related to

Pageof 22
Sort By:
Plos One|August 8, 2013
Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in miceKirsi Tamminen, Suvi Lappalainen, Leena Huhti, et al.
Virology|August 28, 2017
Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigensSuvi Heinimäki, Kirsi Tamminen, Maria Malm, et al.
Mbio|March 28, 2023
Viral Gastroenteritis: Sickness Symptoms and Behavioral ResponsesArash Hellysaz, Magdalena Neijd, Timo Vesikari, et al.
Expert Review of Vaccines|October 25, 2023
PreHevbrio: the first approved 3-antigen hepatitis B vaccineTimo Vesikari, Joanne M Langley, Vlad Popovic, et al.
Scientific Reports|March 3, 2019
Development of T cell immunity to norovirus and rotavirus in children under five years of ageMaria Malm, Heikki Hyöty, Mikael Knip, et al.
Human Vaccines & Immunotherapeutics|August 22, 2012
Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of ageTimo Vesikari, Stéphanie Pepin, Inca Kusters, et al.
Microbes and Infection|March 18, 2014
Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assaysHanni Uusi-Kerttula, Kirsi Tamminen, Maria Malm, et al.
The Pediatric Infectious Disease Journal|July 26, 2016
Decrease of Rotavirus Gastroenteritis to a Low Level Without Resurgence for Five Years After Universal RotaTeq Vaccination in FinlandMaria Hemming-Harlo, Jukka Markkula, Leena Huhti, et al.
Vaccine|September 13, 2011
Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding studyGiovanni Della Cioppa, Timo Vesikari, Etienne Sokal, et al.
The Pediatric Infectious Disease Journal|May 6, 2010
Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccineTimo Vesikari, Aino Karvonen, Shannon Allen Ferrante, et al.
Pageof 22

Showing results (61-70 of 211) with videos related to

Sort By:
Pageof 22
Plos One|August 8, 2013
Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in miceKirsi Tamminen, Suvi Lappalainen, Leena Huhti, et al.
Virology|August 28, 2017
Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigensSuvi Heinimäki, Kirsi Tamminen, Maria Malm, et al.
Mbio|March 28, 2023
Viral Gastroenteritis: Sickness Symptoms and Behavioral ResponsesArash Hellysaz, Magdalena Neijd, Timo Vesikari, et al.
Expert Review of Vaccines|October 25, 2023
PreHevbrio: the first approved 3-antigen hepatitis B vaccineTimo Vesikari, Joanne M Langley, Vlad Popovic, et al.
Scientific Reports|March 3, 2019
Development of T cell immunity to norovirus and rotavirus in children under five years of ageMaria Malm, Heikki Hyöty, Mikael Knip, et al.
Human Vaccines & Immunotherapeutics|August 22, 2012
Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of ageTimo Vesikari, Stéphanie Pepin, Inca Kusters, et al.
Microbes and Infection|March 18, 2014
Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assaysHanni Uusi-Kerttula, Kirsi Tamminen, Maria Malm, et al.
The Pediatric Infectious Disease Journal|July 26, 2016
Decrease of Rotavirus Gastroenteritis to a Low Level Without Resurgence for Five Years After Universal RotaTeq Vaccination in FinlandMaria Hemming-Harlo, Jukka Markkula, Leena Huhti, et al.
Vaccine|September 13, 2011
Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding studyGiovanni Della Cioppa, Timo Vesikari, Etienne Sokal, et al.
The Pediatric Infectious Disease Journal|May 6, 2010
Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccineTimo Vesikari, Aino Karvonen, Shannon Allen Ferrante, et al.
Pageof 22